TRISENOX (arsenic trioxide) - Important Safety Information from Teva Pharmaceuticals as approved by the HPRA

Notice type: 3rd Party Publications

Date: 06/11/2020




Problem Or Issue:

Important Safety Information from Teva Pharmaceuticals Ireland on risk of medication errors due to the introduction of 2 mg/ml concentration:

New concentration: 2 mg/ml vial to replace current approved 1 mg/ml glass ampoule of TRISENOX

Important Safety Information - TRISENOX (arsenic trioxide)




« Back